Related Experiment Video
Updated: Mar 12, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
23.2K
Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration
Yuan Gao1, Yunyi Gao2, Dong Ji3
1Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Journal of Clinical and Translational Hepatology
|March 11, 2026
Summary
Selective SGLT2 inhibitors show promise for managing cirrhotic ascites by targeting renal sodium retention. These drugs may reduce ascites and decompensation events in patients with liver cirrhosis.
Area of Science:
- Nephrology
- Gastroenterology
- Pharmacology
Background:
- Cirrhotic ascites results from portal hypertension and neuro-hormonal activation causing renal sodium-water retention.
- Proximal tubular sodium reabsorption, mediated by sodium/hydrogen exchanger 3 (NHE3), is crucial in this process.
- Spatial coupling of NHE3 and sodium-glucose cotransporter 2 (SGLT2) suggests a therapeutic target.
Purpose of the Study:
- To review the molecular mechanisms of SGLT2 inhibitors in cirrhotic ascites.
- To evaluate emerging clinical evidence for SGLT2 inhibitors in managing cirrhotic ascites.
Main Methods:
- Review of molecular mechanisms linking SGLT2 inhibition to NHE3 activity.
- Analysis of early clinical investigations, including case reports, retrospective studies, and pilot randomized trials.
Main Results:
- SGLT2 inhibition suppresses NHE3 activity, reducing sodium reabsorption.
- Increased sodium chloride delivery to the macula densa modulates tubuloglomerular feedback and the renin-angiotensin-aldosterone system.
- Early studies suggest potential benefits in ascites control and reduced decompensation events, though limited by small sample sizes and observational designs.
Conclusions:
- SGLT2 inhibitors represent a potential therapeutic strategy for cirrhotic ascites.
- Further robust clinical trials are needed to confirm efficacy and generalizability.
- Understanding the interplay between SGLT2, NHE3, and renal physiology is key to optimizing treatment.
More Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
307
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
01:32Secondary Active Transport
12.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
12.7K
01:55Secondary Active Transport
139.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
139.7K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247